Clinical Trials Browser

Phase 2 × Head and Neck Neoplasms × Gefitinib × Clear all

NCT01185158 2023-11-29

A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma

Phase 2 Completed

46 enrolled

Head & Neck

Lymphoid Interstitial Pneumonia, Head and Neck Neoplasms, Laryngeal Diseases

NCT01185171 2023-05-11

Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer

Phase 2 Completed

70 enrolled 11 charts

Head & Neck

Lymphoid Interstitial Pneumonia, Head and Neck Neoplasms, Laryngeal Diseases

NCT00095836 2017-05-31

Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy

Phase 2 Completed

27 enrolled 16 charts

EndocrineHead & Neck

Thyroid Cancer, Papillary, Head and Neck Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary, Thyroid Carcinoma, Anaplastic

NCT01405846 2016-08-19

TIDAL1

Phase 2 Terminated

32 enrolled

Head & NeckThoracic

Head and Neck Neoplasms, Lung Neoplasms

NCT00519077 2016-07-01

Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck

Phase 2 Completed

44 enrolled 7 charts

Head & Neck

Carcinoma, Head and Neck Neoplasms, Neoplasms

NCT00015964 2013-09-05

ZD 1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck

Phase 2 Completed

51 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT00024089 2013-02-11

Gefitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer

Phase 2 Completed

60 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT00233636 2011-01-27

Iressa and Radiotherapy in the Treatment of the Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck

Phase 2 Withdrawn

28 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT00242762 2011-01-27

ZD1839 (IRESSA™) in Combination With Docetaxel & Cisplatin in Subjects With Metastatic Head & Neck Cancer

Phase 2 Completed

36 enrolled

Head & Neck

Head and Neck Neoplasms

NCT00193284 2010-06-22

Chemotherapy Plus Gefitinib Followed by Chemotherapy, Radiation Therapy, and Gefitinib For Head and Neck Cancer

Phase 2 Completed

50 enrolled

Head & Neck

Head and Neck Neoplasms

NCT00242749 2009-04-23

IRESSA in Combination With Cisplatin & Radiotherapy in Patients With Advanced Head & Neck Carcinoma

Phase 2 Completed

47 enrolled

Head & Neck

Head and Neck Neoplasms

NCT00255476 2009-04-23

The IRESSA Novel Head and Neck Chemotherapy Evaluation Study

Phase 2 Completed

64 enrolled

Head & Neck

Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT00228488 2007-12-19

Effect of Iressa With/Without Concurrent Chemoradiotherapy on Tumor Gene Expression Profiles in Patients With Advanced Non-Nasopharyngeal Head and Neck Carcinoma

Phase 2 Completed

60 enrolled

Head & Neck

Head and Neck Neoplasms